These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31586853)

  • 21. Cytohematologic and cytogenetic prognostic factors at diagnosis and in the evolution in 46 primary myelodysplastic syndromes.
    González Manso AI; García Marcilla A; Barreiro E; Gilsanz F
    Cancer Genet Cytogenet; 1992 Jul; 61(2):174-82. PubMed ID: 1638500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic significance of serial determinations of lactate dehydrogenase in follow-up for patients with myelodysplastic syndrome].
    Zhang YQ; Dai HB; Wang JH; Li XY; Dai SM; Yao DD; Ma LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):85-9. PubMed ID: 21362228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes.
    Hast R; Nilsson I; Widell S; Ost A
    Leuk Res; 1989; 13(2):173-8. PubMed ID: 2927174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies.
    Pardanani A; Drake MT; Finke C; Lasho TL; Rozell SA; Jimma T; Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1013-6. PubMed ID: 22086864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes.
    Kárai B; Bedekovics J; Miltényi Z; Gergely L; Szerafin L; Ujfalusi A; Kappelmayer J; Hevessy Z
    Int J Lab Hematol; 2017 Dec; 39(6):577-584. PubMed ID: 28625017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical study on the serum carcinoembryonic antigen, CA 19-9, CA 50 and alpha-fetoprotein levels in patients with myelodysplastic syndromes.
    Dalamaga M; Karmaniolas K; Kontos F; Migdalis I; Dionyssiou-Asteriou A
    Leuk Lymphoma; 2006 Sep; 47(9):1782-7. PubMed ID: 17064988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review].
    Xu YY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):285-9. PubMed ID: 26913438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classifications.
    Breccia M; D'Elia GM; Cannella L; Stefanizzi C; Fama A; Federico V; Santopietro M; Alimena G
    Leuk Lymphoma; 2009 May; 50(5):841-3. PubMed ID: 19452321
    [No Abstract]   [Full Text] [Related]  

  • 31. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.
    Zhang X; Sokol L; Bennett JM; Moscinski LC; List A; Zhang L
    Leuk Res; 2016 Apr; 43():18-23. PubMed ID: 26927701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Automated neutrophil morphology and its utility in the assessment of neutrophil dysplasia.
    Miguel A; Orero M; Simon R; Collado R; Perez PL; Pacios A; Iglesias R; Martinez A; Carbonell F
    Lab Hematol; 2007; 13(3):98-102. PubMed ID: 17984041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
    Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
    Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
    Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary myelodysplastic syndrome in children].
    Kuzmanović M; Bunjevacki G; Rasović N; Vujić D; Mićić D; Guć-Sćekić M; Jovanović V
    Srp Arh Celok Lek; 2001; 129 Suppl 1():10-6. PubMed ID: 15637984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
    Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
    Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.
    Park S; Sapena R; Kelaidi C; Vassilieff D; Bordessoule D; Stamatoullas A; Cheze S; Beyne-Rauzy O; Vey N; Rose C; Guerci A; Natarajan-Amé S; Tertian G; Slama B; Fenaux P; Dreyfus F
    Leuk Res; 2011 Nov; 35(11):1530-3. PubMed ID: 21803419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes.
    Cesana C; Klersy C; Brando B; Nosari A; Scarpati B; Scampini L; Molteni A; Nador G; Santoleri L; Formenti M; Valentini M; Mazzone A; Morra E; Cairoli R
    Leuk Res; 2008 Nov; 32(11):1715-23. PubMed ID: 18456323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Myelodysplastic syndrome. Main symptoms: mostly nonspecific anemia symptoms].
    Kolyvanos Naumann U; Nigg C; Käser L; Vetter W
    Praxis (Bern 1994); 2005 Jul; 94(28-29):1095-100; quiz 1101. PubMed ID: 16078749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.